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Abstract 
Patients with neuroendocrine tumors (NETs) can be treated with peptide receptor radionuclide therapy 
(PRRT). Here, the somatostatin analogue octreotate radiolabeled with lutetium-177 is targeted to NET 
cells by binding to the somatostatin receptor subtype 2 (SST2). During radioactive decay, DNA damage is 
induced, leading to NET cell death. Although the therapy proves to be effective, mortality rates remain 
high. To appropriately select more optimal treatment strategies, it is essential to first better understand 
the radiobiological responses of tumor cells to PRRT.  
Methods: We analyzed PRRT induced radiobiological responses in SST2 expressing cells and xenografted 
mice using SPECT/MRI scanning and histological and molecular analyses. We measured 
[177Lu]Lu-DOTA-TATE uptake and performed analyses to visualize induction of DNA damage, cell death 
and other cellular characteristics.  
Results: The highest accumulation of radioactivity was measured in the tumor and kidneys. PRRT 
induced DNA damage signaling and repair in a time-dependent manner. We observed intra-tumor 
heterogeneity of DNA damage and apoptosis, which was not attributed to proliferation or bioavailability. 
We found a strong correlation between high DNA damage levels and high SST2 expression. PRRT elicited 
a different therapeutic response between models with different SST2 expression levels. Heterogeneous 
SST2 expression levels were also confirmed in patient NETs.  
Conclusion: Heterogeneous SST2 expression levels within NETs cause differentially induced DNA 
damage levels, influence recurrent tumor phenotypes and impact the therapeutic response in different 
models and potentially in patients. Our results contribute to a better understanding of PRRT effects, 
which might impact future therapeutic outcome of NET patients. 
Key words: Peptide receptor radionuclide therapy, neuroendocrine tumors, somatostatin receptor subtype 2, 
radiobiology, DNA damage response 
Introduction 
Neuroendocrine tumors (NETs) form a 
heterogeneous group of tumors, nonetheless 70-100% 
of differentiated NETs highly express the 
somatostatin receptor subtype 2 (SST2) on their cell 
membrane [1]. These receptors can be targeted with 
radiolabeled somatostatin analogues, such as 
[Tyr3]octreotate, for diagnostics or therapy [2, 3]. 
Peptide receptor radionuclide therapy (PRRT) using 
[Tyr3]octreotate labeled with the β-particle emitter 
lutetium-177 ([177Lu]Lu-DOTA-[Tyr3]octreotate or 
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[177Lu]Lu-DOTA-TATE) has proven to be an effective 
therapy for patients with non-operable or metastatic 
SST2 positive NETs in terms of improving progression 
free survival (PFS) and quality of life [4, 5]. 
During PRRT, [177Lu]Lu-DOTA-TATE is targeted 
to NETs via SST2 binding and will deliver a cytotoxic 
radiation dose to the cancer cells [6]. PRRT 
outperforms other available treatments for 
metastasized NETs on various levels, but 
unfortunately still lacks the efficacy for complete 
remission in the majority of patients [5]. Increasing 
the therapeutic efficacy might be accomplished by 
changing the treatment planning (time interval or 
dosing), by developing new targeting biomolecules [7, 
8], by using more powerful radionuclides [9] or by 
combining PRRT with other treatments, such as DNA 
damage repair modulating compounds [10].  
Before the best PRRT optimization strategy can 
be determined, it is essential to first better understand 
the biological effects of ionizing radiation, i.e. 
radiobiology. However, until now little information is 
available [11]. In sharp contrast, radiobiological 
principles of external beam radiotherapy (EBRT) have 
been studied for decades and these studies have 
significantly contributed to breakthroughs in 
improving effectiveness of EBRT [12]. Unfortunately, 
due to fundamental differences in radiation qualities 
between EBRT and PRRT, such as dose-rate and 
continuous radiation versus single or fractionated 
doses, extrapolation of radiobiological knowledge is 
not straightforward [13]. To make calculated decisions 
for therapy optimization, first a better understanding 
of the radiobiological effects of PRRT has to be 
obtained [11]. For this purpose, we dissected 
radiobiological responses of PRRT in different in vivo 
and in vitro SST2 expressing models. Our analyses 
showed that important biological parameters, such as 
SST2 expression levels, can differ within and between 
models and human NET samples. Furthermore, we 
have demonstrated that differential SST2 expression 
levels are an important determinant for some 
radiobiological effects of PRRT in NET cells. 
Methods 
Cell culture and in vitro treatment 
NCI-H69 cells (ATCC) were cultured in Rosewell 
Park Medium Institute 1638 medium (RPMI-1638) 
(Sigma-Aldrich) supplemented with penicillin (50 
units/mL), streptomycin (50 µg/mL) (Pen/Strep) and 
10% fetal calf serum (FCS). CA20948 [14] cells were 
cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Gibco) supplemented with Pen/Strep and 
10% FCS. Cells were cultured at 37 oC and 5% CO2. 
The molar activity of [177Lu]Lu-DOTA-TATE 
used in vitro was 37 MBq/µg with a purity > 95%. 
Both CA20948 and NCI-H69 cells were incubated with 
1 MBq/mL [177Lu]Lu-DOTA-TATE for 4 h at 37 oC. 
NCI-H69 cells were spun down on a glass slide using 
a cytospin centrifuge (Rotofix 32A, Hettich) for 6 
minutes at 347 g at room temperature (RT). CA20948 
cells were washed and fixed on coverslips. Fixation 
was done using 2% paraformaldehyde (PFA) for 20 
minutes at RT and samples were stained according to 
protocol (see below).  
Animal experimental conditions 
Animal experiments were approved by the 
Animal Welfare Committee of the Erasmus MC and 
were conducted in accordance with European 
guidelines. Animal experiments included a time series 
for analyses of radiobiological parameters in NCI-H69 
xenografts and survival cohorts with NCI-H69 or 
CA20948 xenografts. For both animal experiments 30 
MBq/0.5 µg [177Lu]Lu-DOTA-TATE was labeled as 
previously described with a purity of > 95% [15]. All 
animals received a single injection of 30 MBq 
[177Lu]Lu-DOTA-TATE. 
Human NET tissue samples 
Pancreatic NET tissue was obtained from 
patients undergoing surgery. Tissue was obtained 
according to the code of proper secondary use of 
human tissue in the Netherlands established by the 
Dutch Federation of Medical Scientific Societies and 
approved by the local Medical Ethical committees. 
Specimens were coded anonymously. 
In vivo treatment for radiobiological analysis 
BALB-c/nude mice were engrafted 
subcutaneously with 5 x 106 NCI-H69 cells in 200 µl 
Hanks Balanced Salt Solution (HBSS) (Gibco, 
14065056) containing 33,3% Matrigel (Corning, 
354248). Tumor volumes were measured every 2 days 
by palpation and at a tumor size of 369 ± 203 mm3 
mice were injected intravenously: 100 µL (40 g/L) 
gelofusine (Braun Medical) and after 2 minutes 30 
MBq/0,5 µg [177Lu]Lu-DOTA-TATE in 0,1% Bovine 
serum albumin (BSA) in phosphate buffered saline 
(PBS) (Sigma, D8537-500 mL) (n = 4 per group). Mice 
were sacrificed by cervical dislocation and analyzed at 
1 h, 1, 2, 3, 4, 5, 7, 9, 11 and 14 days post injection (p.i.). 
Organs were put in a gamma-counter for 
measurement of radioactive uptake and then fixed in 
formalin for 1 day at RT and stored in 70% ethanol 
until they were embedded in paraffin. Uninjected 
animals were used as control (n = 4).  
In vivo treatment for survival analysis 
BALB-c/nude mice were engrafted 
subcutaneously with 5 x 106 NCI-H69 cells in 200 µl 
HBSS containing 33,3% Matrigel or with 5 x 106 
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CA20948 cells in 200 µl HBSS. Mice with NCI-H69 
tumors (n = 8) were injected when tumor volumes 
reached 697 ± 256 mm3 and mice with CA20948 
tumors (n = 9) when tumor reached 318 ± 216 mm3. 
Both groups were compared to vehicle injected 
counterparts (n = 8 and n = 6, respectively). Tumor 
volumes were measured three times per week p.i. 
Mice were sacrificed when tumor volumes reached 
the humane endpoint of 2000 mm3. Tumors were 
fixed in formalin for 1 day at RT and stored in 70% 
ethanol until they were embedded in paraffin. 
In vivo single photon emission computed 
topology/magnetic resonance imaging 
(SPECT/MRI) 
On each time-point p.i. SPECT/MRI-scans were 
performed post mortem on one mouse per group in 
the radiobiology cohort. SPECT/MRI was performed 
using a 4-head multipinhole SPECT/MRI system 
(NanoScan; Mediso Medical Imaging). SPECT images 
were acquired in 30 min (28 projections; 60 
s/projection). Maximum Likelihood Estimation 
Method image reconstruction was performed with 32 
iterations showing full signal recovery. MRI of the 
mice was done using a T1 gradient echo sequence 
(repetition time/echo time, 12/2 ms, 1 average) and 
T2-weighted images were acquired using a and a spin 
echo sequence (repetition time/echo time, 4,500/41 
ms, 4 averages). The other scan parameters included a 
70-mm field of view, a 128 × 128 matrix, and a 1-mm 
slice thickness. The MRI images were used to 
delineate tumor tissue and were quantified using the 
scanner software (Nucline, version 3; Mediso Medical 
Imaging). On the T2-weighted MR images, a region of 
interest was drawn around the tumor that best 
showed the tissue boundaries. The total SPECT 
uptake within the region of interest was divided by 
the tumor volume to give a volumetric uptake 
(kBq/mm3). 
Pharmacokinetics and dosimetry assessments 
The biodistribution data were analyzed to 
determine the kinetics of the activity in organs and 
tumors. The measured activity data as a function of 
time were fitted with single or double exponential 
curves using the least-square regression method with 
Graphpad Prism version 5 (graphpad.com). Decisions 
on to use a single or a double exponential curve was 
based on the (corrected) Akaike’s information 
criterion [16]. The time-activity curves were 
integrated over time to determine the time-integrated 
activity coefficients after folding in the lutetium-177 
decay function. Absorbed doses in all organs and in 
the tumor were calculated by using the MIRD 
equation with the lutetium-177 S-values for a 22 g 
mouse Moby phantom, kindly provided by Dr Erik 
Larsson [17].  
Hematoxylin and eosin (H&E) staining 
Paraffin tissue sections of 4 µm were cut using a 
microtome (Microm, 800-1683). Slides were dried 
overnight at 37 °C. Sections were deparaffinized in 
xylene and rehydrated in decreasing alcohol 
concentrations. Sections were then incubated in 
Harris Hemotoxylin (Sigma-Aldrich, HHs16) for 1 
min at RT and subsequently in eosin yellowish 
solution (AppliChem, 251299) for 1 minute. Slides 
were then dehydrated in increasing alcohol 
concentrations and cleared in xylene. The slides were 
mounted using pertex (Histolab, 00811). Images were 
procured using a BX40 light microscope (Olympus).  
Antibodies 
For immunofluorescent (IF) stainings p53 
binding protein 1 (53BP1) (Novus Biologicals, 
NB100-904; 1:500), phosphorylated histone 2AX 
(γH2AX) (Millipore, JBW301; 1:250), SST2 (Abcam, 
134152; 1:100) and Cluster of differentiation 31 (CD31) 
(Abcam, ab28364; 1:100) primary antibodies were 
used. Secondary antibodies used are 
donkey-anti-rabbit IgG Alexa Fluor 594 (Thermo 
Fisher, A-11078; 1:500) and donkey-anti-mouse IgG 
Alexa Fluor 488 (Thermo Fisher; A-11005; 1:500). For 
immunohistochemical stainings (IHC) Ki-67 (Abcam, 
ab15580; 1:200) was used. Here, the secondary 
antibody used is Peroxidase donkey-anti-rabbit IgG 
(Jackson Immunoresearch, 711-035-152; 1:2000). 
Immunofluorescent stainings 
Cells were IF stained as previously described 
[10]. Briefly, tissue sections were deparaffinized as 
described above. Then antigen retrieval was 
performed by boiling slides for 20 minutes in pH 6 
(for cytoplasmic antigens) or pH 9 (for nuclear 
antigens) antigen retrieval buffer (DAKO) and cooling 
down to RT. Tissues were permeabilized with 
PBS+0.5% Triton (PBS(T)) at RT and blocked with 3% 
BSA in PBS(T) at RT. Sections were incubated with 
primary antibodies overnight at 4 °C in block buffer 
and with secondary antibodies for 60 minutes at RT. 
Mounting was done using Vectashield containing 
DAPI (Vector labs, H-1200). 
Immunohistochemical stainings 
Tissue sections of 4 µm were deparaffinized and 
rehydrated. Samples were then incubated in 3% H2O2 
(Honeywell, 95299) in methanol (Honeywell, 
32213-2.5l) for 20 minutes at RT. Slides were washed 
with tap water and boiled in pH 6 Antigen Retrieval 
buffer for 20 minutes. Slides were incubated in 
blocking solution (PBS 5%BSA), following with the 
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primary antibody in blocking solution overnight at 4 
°C and with the secondary antibody in blocking 
solution for 90 minutes at RT. Slides were washed and 
incubated for 1 minute in DAB-solution (DAKO, 
K3468). The slides were dehydrated, cleared and then 
mounted using Pertex (Histolab, 00811). Images were 
procured using a BX40 light microscope (Olympus). 
Quantification was performed in ImageJ by using 
particle analysis after.  
TUNEL assay 
Tissue sections of 4 µm were deparaffinized and 
rehydrated. TUNEL assay was performed using the In 
Situ Cell Death Detection Kit, Fluorescein (Roche, 
11684795910) according to manufacturer’s 
instructions.  
Confocal microscopy and quantification 
53BP1 and γH2AX focus formation was imaged 
with a Leica SP5 confocal microscope (Leica) using 
Z-stack acquisition. For tile-scan analyses a LSM700 
confocal microscope (Zeiss) was used. Tiles were 
stitched, thresholded and quantified using ImageJ.  
ImageJ was utilized to apply the same local 
threshold (default for DAPI, MaxEntropy for SST2) to 
all images in order to segment nuclei or quantify 
DAPI signal and quantify IF signal. Foci were 
quantified using the Find Maxima function. 
Statistical analyses and mathematical models 
Statistical analyses were performed in GraphPad 
Prism version 8.2.1. Analyses conducted were 
unpaired Student t-tests or one-way ANOVA 
followed by Bonferroni’s or Tukey’s test for multiple 
comparisons or Browne-Forsythe and Welch posttest 
for comparisons to control samples. For the 
correlation between SPECT and ex vivo bio 
distribution data the Pearson correlation was 
performed. All tests with values of p < 0.05 are 
assumed significant. 
Results 
Biodistribution of [177Lu]Lu-DOTA-TATE 
shows high radioactive uptake in tumors and 
kidneys 
To evaluate the in vivo distribution of 
[177Lu]Lu-DOTA-TATE, we performed SPECT 
imaging and measured radioactivity ex vivo in excised 
organs of NCl-H69 xenografted mice. Accumulation 
of lutetium-177 was visualized by SPECT starting 
from 1 h p.i. with the highest accumulated uptakes in 
the tumor and kidneys (Figure 1A; Figure S1A). The 
highest level of lutetium-177 retained in the tumors, 
which could be visualized up to 14 days p.i. by SPECT 
and γ-counter measurements (Figure 1A-B; Figure 
S1A). Inferring from the ex vivo biodistribution data 
we found an increasing tumor-to-kidney ratio over 
time, ranging from 1.01 ± 0.18 to 17.50 ± 4.52 at 1 h and 
14 days p.i., respectively (Figure 1C). Furthermore, we 
have calculated the absorbed dose in all analyzed 
organs and found substantial absorbed doses received 
by both tumor and kidney of 10.08 ± 0.35 Gy and 3.5 ± 
0.12 Gy, respectively and an absorbed dose ranging 
from 0.22 to 1.48 Gy for the other organs (Figure 1D; 
Figure S1B). 
When quantifying the level of lutetium-177 on 
the SPECT scans, we observed a distribution very 
similar to the measured radioactivity ex vivo in the 
tumors and kidneys (Figure 1E-F; Figure S1C). 
Therapeutic response is induced 
heterogeneously in the tumors 
To investigate the therapy response of the 
NCl-H69 tumors at the cellular level, we performed 
histochemical analyses. H&E stainings of the different 
tumors showed large pyknotic and disintegrating 
regions starting from 2 days p.i. of 
[177Lu]Lu-DOTA-TATE, indicating induction of cell 
death. These regions were heterogeneously 
distributed in the tumors and were diverse in size. 
Also, these regions became more prominent until day 
7 p.i. (Figure 2A; Figure S2). 
To further analyze the kinetics and heterogeneity 
of cell death induction, we performed a TUNEL assay, 
which stains cells with fragmented DNA, indicating 
apoptosis (Figure 2B). The level of TUNEL signal 
started increasing from 3 days p.i. TUNEL signal 
reached the highest level 4 and 5 days p.i. with an 
average of 50% and 47% TUNEL positive areas, 
respectively (Figure 2C). The fraction of TUNEL 
positive cells then declined to an average of 26% at 14 
days after treatment. We observed a large variation in 
size and distribution of TUNEL positive areas, which 
was corroborated as a large spread in the 
quantification (Figure 2C).  
Furthermore, we measured the therapeutic effect 
in an additional group of mice. Tumor growth curves 
showed that 5 days p.i. of [177Lu]Lu-DOTA-TATE 
NCI-H69 tumors start to decrease in volume to 71% of 
the starting volume at 14 days p.i., upon which 
regrowth occurred (Figure 2D). 
DNA double strand breaks are induced in a 
heterogeneous manner 
The therapeutic response of [177Lu]Lu-DOTA- 
TATE can be attributed to induction of DNA damage 
of which DNA double strand breaks (DSBs) are the 
most cytotoxic [18]. Therefore, we investigated the 
level of PRRT-induced DSBs and their repair kinetics 
on the different time-points p.i. [19]. IF staining of the 
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DNA damage markers 53BP1 and γH2AX, showed a 
strong induction DNA damage response (Figure 2E). 
53BP1 foci was observed from 1 h p.i. (Figure 2F). A 
further increase and large spread in the number of foci 
per cell was observed at 1 and 2 days p.i. to an 
average of 2.3 ± 2.2 and 2.0 ± 1.3 respectively, after 
which the number 53BP1 foci declined again, yet 
remained significantly higher than tumors from 
vehicle treated animals. We observed a 5-fold increase 
in the number of γH2AX foci 2 days p.i. to 1.1 ± 0.5 
foci per cell per which retained significantly higher 
than NT controls throughout all time-points. For both 
markers intra-tumor heterogeneity was observed. 
Interestingly, 53BP1 and γH2AX foci did not 
colocalize in all cells. 
 
 
Figure 1. In vivo and ex vivo biodistribution of [177Lu]Lu-DOTA-TATE in NCl-H69 xenografted mice. (A) SPECT/MRI scans of [177Lu]Lu-DOTA-TATE injected 
mice at different time-points (n = 1). (B) The biodistribution measured ex vivo over time in percentage of injected dose per gram of [177Lu]Lu-DOTA-TATE in the tumor and 
healthy organs (n = 4). Error bars indicate standard deviation. (C) The [177Lu]Lu-DOTA-TATE uptake tumor-to-kidney ratio over time based on the biodistribution data. Error 
bars indicate standard deviation. (D) The total absorbed dose of the tumor and healthy organs based on the ex vivo bio distribution data. Error bars indicate standard deviation 
(n = 4). (E) Comparison of the biodistribution (left Y-axis) and SPECT (right Y-axis) measurements of radioactivity in the tumor and kidney. (F) Pearson’s correlation of the 
biodistribution measured ex vivo and SPECT measurements of accumulated radioactivity in tumors. 
Theranostics 2021, Vol. 11, Issue 2 
 
 
http://www.thno.org 
496 
 
Figure 2. Histological analysis of [177Lu]Lu-DOTA-TATE induced cell death and DNA damage. (A) Representative H&E images and zoom of NCI-H69 tumors of 
non-treated (NT) mice and 5 days after [177Lu]Lu-DOTA-TATE injection. (B) Representative TUNEL tile-scan images and zoom of NCI-H69 tumors of non-treated mice and 5 
days after [177Lu]Lu-DOTA-TATE injection. (C) Quantification of the TUNEL signal in DAPI stained cells of 25 fields of view per tumor sample (n = 4). Error bars indicate 
standard error of the mean. (D) Tumor growth curves of NCI-H69 tumors after vehicle (blue) or [177Lu]Lu-DOTA-TATE (red) injection of the mice. Error bars indicate standard 
error of the mean (vehicle n = 9, [177Lu]Lu-DOTA-TATE n = 8). (E) Representative images of DNA damage markers 53BP1 (red) and γH2AX (green) in NCI-H69 tumors of NT 
mice or 2 or 14 days after [177Lu]Lu-DOTA-TATE injection. (F) Quantification of 53BP1 (left panel) and γH2AX (right panel) foci in cells in 5 field of view in NCI-H69 tumors NT 
mice or at different time points post [177Lu]Lu-DOTA-TATE injection. Error bars indicate standard error of the mean. 
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The heterogenic therapy response is not 
explained by variation in proliferation and 
bioavailability 
Although it is often assumed that cell 
line-derived tumors have a homogenous composition, 
we observed a heterogenic intra-tumoral therapy 
response. Therefore, we investigated whether the 
distribution of cycling cells could underlie this 
heterogenic therapy response by measuring Ki-67 
expression (Figure 3A). The NCl-H69 tumors showed 
a homogeneous distribution of cycling cells. 
Quantification of the fraction of cycling cells in 
non-apoptotic regions showed 60.96 ± 5.32% cycling 
cells in all samples regardless of therapy, the only 
exception being 2 days after treatment, where the 
level of Ki-67 positive cells was significantly increased 
to 74.13% (Figure 3B).  
Another possibility that can augment therapy 
response is the bioavailability of a drug to different 
parts of a tumor. Therefore, we analyzed the 
vascularization of the tumors by staining for the 
endothelial cell marker CD31 in NT and tumors 2 d 
p.i. Here, we observed an equal distribution of blood 
vessels in the whole tumors (Figure 3C). Moreover, 
we analyzed the proximity of DNA damage to blood 
vessels by combining IF stainings of CD31 with 
γH2AX at 2 days p.i. with [177Lu]Lu-DOTA-TATE.   
No correlation between presence of 
CD31-positive vessels and level of induced DNA 
damage was found in these tumors as γH2AX foci 
were observed regardless of the distance to blood 
vessels (Figure 3D). 
DNA damage levels induced by 
[177Lu]Lu-DOTA-TATE are correlated to SST2 
expression levels  
To further investigate the heterogeneous therapy 
response, we analyzed SST2 expression levels. SST2 
membrane staining was observed in all tumor cells 
and interestingly, the SST2 expression levels differed 
greatly between clustered NCl-H69 cells within all 
tumors (Figure 4A). 
To investigate whether the differential SST2 
expression influenced the level of [177Lu]Lu-DOTA- 
TATE induced DNA damage, we performed a 
co-staining of SST2 with γH2AX (Figure 4B). No 
significant difference in baseline γH2AX foci in cells 
of SST2high and SST2low regions was observed in tumors 
of the non-treated mice. Moreover, SST2low cells in the 
tumors of treated mice showed no significant increase 
in the number of γH2AX foci compared to SST2low 
cells in tumors of non-treated mice. However, we 
observed a significant increase in the number of 
γH2AX foci in SST2high cells in tumors from treated 
mice compared to non-treated SST2high regions. 
Moreover SST2high cells showed a significantly higher 
number of γH2AX foci compared to SST2low cells in 
tumors from [177Lu]Lu-DOTA-TATE treated mice 
(Figure 4C). 
Overall the fraction of SST2high cells reduced over 
time (Figure 4D). Tumors from non-treated mice and 
from 2 days p.i. of [177Lu]Lu-DOTA-TATE showed 
36% and 38% SST2high expressing areas, respectively. 
Interestingly, tumors at 5 days and 11 days p.i. 
showed a strong reduction of SST2 expression to a 
fraction of 9% and 14% SST2high cells, respectively 
(Figure 4E).  
SST2 expression levels differ between 
CA20948 and NCI-H69 cells and influence 
[177Lu]Lu-DOTA-TATE uptake 
To corroborate the correlation between SST2 
expression levels, radioactive uptake and DNA 
damage, we performed [177Lu]Lu-DOTA-TATE 
treatment in vitro. We measured a significant increase 
in the level of 53BP1 and γH2AX foci per cell in 
NCl-H69 cells at 1 day post treatment compared to 
non-treated cells, with a large variation in the number 
of foci per cell (Figure 5A-B; Figure S3). A continued 
presence of elevated of γH2AX and 53BP1 foci was 
observed from day 3 until at least day 7 after 
treatment. 
Staining of SST2 in NCI-H69 cells again revealed 
differential receptor expression among the cells 
(Figure 5C). In order to determine whether this is 
universal or not for SST2 positive models, we 
analyzed the SST2 expression in CA20948 cells, a rat 
pancreatic cancer cell line which is frequently used in 
PRRT research [14]. In these cells, we observed a 
much more homogenous distribution of SST2 
expression levels compared to NCI-H69 (Figure 5C). 
Upon [177Lu]Lu-DOTA-TATE treatment of both 
cell lines we observed a 3 fold higher uptake of 
radioactivity in CA20948 compared to NCI-H69 
(Figure S4A). Moreover we observed more SST2 
internalization directly after incubation with 
[177Lu]Lu-DOTA-TATE in cells that have higher 
expression of SST2 compared to their lower expressing 
counterparts in both CA20948 and NCI-H69 cells 
(Figure S4B). In line with this and what was found in 
vivo, we observed that in NCI-H69 cells a significant 
higher number of γH2AX foci in the SST2high cells was 
measured after [177Lu]Lu-DOTA-TATE in vitro 
treatment compared to SST2low cells (Figure 5D-E; 
Figure S5). 
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Figure 3. Analysis of Ki-67 status and vasculature in correlation with DNA damage levels. (A) Representative image of the Ki-67 staining of NCI-H69 tumors of 
non-treated mice. (B) Quantification of Ki-67-positive cells over time. ***p < 0.001 compared to NT. Error bars indicate standard error of the mean. (C) Representative tile-scan 
image of CD31 staining of a NT NCI-H69 tumor. (D) Representative Z-stack image with zooms of CD31 staining (red) and γH2AX staining (green) of NCI-H69 tumors two days 
post [177Lu]Lu-DOTA-TATE injection. Depicted are areas directly next to vessels (lower panel) and further from vessels (upper panel). 
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Figure 4. Analysis of SST2 expression levels in correlation with DNA damage. (A) Representative tile-scan image with zoom of SST2 stainings of NCI-H69 tumors of 
NT mice. (B) Representative tile-scan image with zoom of SST2 and γH2AX stainings of NCI-H69 tumors 2 days after [177Lu]Lu-DOTA-TATE injection. (C) γH2AX foci 
quantification in SST2high and SST2low regions of NT tumors and 2 days p.i. Error bars indicate the standard error of the mean (n = 4) *p < 0.05, **p < 0.01. (D) Representative 
tile-scan images of SST2 stained tumors 2 and 5 days after [177Lu]Lu-DOTA-TATE injection. (E) Quantification of the fraction of SST2high cells in NCI-H69 tumors of NT mice or 
at different time points post [177Lu]Lu-DOTA-TATE injection. Error bars indicate standard deviation. *p < 0.05, **p < 0.01. 
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Figure 5. In vitro analyses of [177Lu]Lu-DOTA-TATE treatment in a time-dependent manner. (A) Representative images of 53BP1 and γH2AX foci in NCI-H69 cells 
1 day after [177Lu]Lu-DOTA-TATE incubation and NT cells. (B) Quantification of the number of 53BP1 and γH2AX foci per nucleus in NCI-H69 cells in a time-dependent manner 
after incubation with [177Lu]Lu-DOTA-TATE. Error bars indicate 95% confidence interval, *p < 0.05, **p < 0.01, ****p < 0.0001. Two other independent experiments and average 
of all three experiments can be found in Figure S3. (C) Representative IF images of SST2 expression in NT NCI-H69 cells (upper panels) and CA20948 cells (lower panels). (D) 
Representative images of SST2 expression and γH2AX foci in NCI-H69 cells 2 days after incubation with [177Lu]Lu-DOTA-TATE. (E) Quantification of γH2AX foci per nucleus 
in SST2high and SST2low regions in NCI-H69 cells 2 days after incubation with [177Lu]Lu-DOTA-TATE. Error bars indicate 95% confidence interval. Two other independent 
experiments and average hereof can be found in Figure S5. 
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Figure 6. Survival, SST2 expression levels and uptake in different tumor models. (A) The relative tumor volumes in [177Lu]Lu-DOTA-TATE treated mice bearing 
NCI-H69 or CA20948 tumors compared to vehicle treated controls. Error bars indicate standard error of the mean (NCI-H69 tumors: vehicle n = 9, [177Lu]Lu-DOTA-TATE n 
= 8; CA20948 tumors: vehicle n = 6, [177Lu]Lu-DOTA-TATE n = 9). (B) Survival curves of [177Lu]Lu-DOTA-TATE treated mice with NCI-H69 and CA20948 tumors belonging 
to mice in A. (C) Representative tile-scan images of SST2 stainings of vehicle treated NCI-H69 and CA20948 tumors and recurrent tumors. (D) Quantification of SST2high 
expression areas in non-treated NCI-H69 and CA20948 tumors and recurrent tumors. Error bars indicate standard error the of mean (n = 4), **p < 0.01. (F) Representative 
images of SST2 staining of two pancreatic NET samples with homogenous (left panel) and heterogeneous (right panel) expression. More IF stained patient samples can be found 
in Figure S7. 
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SST2 expression levels of CA20948 and 
NCI-H69 tumors impact 
[177Lu]Lu-DOTA-TATE uptake and 
therapeutic response 
To analyze whether differences in SST2 
expression levels can influence therapeutic efficacy, 
we treated CA20948 and NCI-H69 xenografted mice 
with [177Lu]Lu-DOTA-TATE. We observed a stronger 
therapeutic response in CA20948 tumors compared to 
the NCI-H69 tumors: CA20948 tumor bearing mice 
started relapsing at approximately 20 days and 
NCI-H69 tumor bearing mice at 12 days p.i. (Figure 
6A). Moreover, treated CA20948 bearing mice showed 
a median survival of 54 days compared to 34 days of 
NCI-H69 bearing mice (Figure 6B). We analyzed the 
uptake of radioactivity on 2 and 4 days p.i. in the two 
tumor models. The difference in uptake of 
radioactivity was 2.5 fold higher in CA20948 tumors 2 
days p.i. and 4.7 fold higher 4 days p.i. compared to 
NCl-H69 tumors (Figure S6). To investigate whether 
this difference in uptake was caused by receptor 
expression, we analyzed SST2 levels in the two tumor 
models. In accordance with the uptake levels and 
therapy efficacy, a higher SST2 expression was 
observed in non-treated CA20948 tumors compared 
to NCI-H69 tumors. Furthermore, while NCl-H69 
tumors had a heterogeneous expression pattern, 
CA20948 tumors showed a homogeneous SST2 
expression pattern (Figure 6C top panels). Moreover, 
when comparing SST2 expression levels in recurrent 
NCI-H69 and CA20948 tumors, we again observed 
that NCl-H69 tumors exhibit significantly lower 
expression levels, while CA20948 tumors retained 
high and homogeneous expression (Figure 6C-D). To 
determine whether receptor heterogeneity occurred in 
human NETs, we performed SST2 stainings on 
resected tumor samples from NET patients. Here, we 
observed differences in expression levels between 
patients. Furthermore, SST2 heterogeneity was 
observed within these tumors, however to different 
extents between patient samples (Figure 6E; Figure 
S7).  
Discussion 
In this study we dissected important 
radiobiological parameters in SST2 positive tumors 
and cells in the context of PRRT. We observed 
extensive uptake of [177Lu]Lu-DOTA-TATE in the 
tumor which resulted in induction of DNA damage 
and subsequent cell death, which then mitigates over 
time. We noted that these therapeutic effects are 
heterogeneous throughout the NCI-H69 tumors and 
that this can be, at least in part, attributed to the 
heterogeneous distribution of the target receptor 
expression. As SST2 expression levels and its 
intra-tumor distribution differ between the models we 
used, this might underlie the difference in therapeutic 
efficacy and the different recurrent tumor 
phenotypes.  
The high observed [177Lu]Lu-DOTA-TATE 
uptake in the tumor and kidneys corroborates 
previous findings in mice and patients [20]. 
Furthermore, splenic uptake differed between mice 
and patients [21, 22]. [177Lu]Lu-DOTA-TATE showed 
a favorable tumor-to-kidney ratio over time, which is 
also reflected in the calculated total absorbed dose. 
Importantly, data acquired with the SPECT/MRI and 
biodistribution measured ex vivo, even though 
expressed in different dimensions, are in agreement. 
This confirms an earlier study that analyzed renal 
uptake of [177Lu]Lu-DOTA-TATE in rats using similar 
platforms [23]. The correlation between the two 
platforms is strong and the feasibility of SPECT as a 
means of performing dosimetry on absorbed dose in 
NETs therefore supports (pre-)clinical data [24-26]. 
This could instigate dosimetry studies using SPECT as 
a means of evaluating biokinetics and intra-tumoral 
distribution of radioligands in preclinical models, or 
even patients. 
The impact and limiting effects of intra-tumor 
heterogeneity on therapeutic efficacy are reported in 
different cancer models [27, 28]. Such heterogeneity is 
observed for many different parameters, such as 
mutational load [29], epigenetic status [30] and 
specific protein expression levels [31]. This 
heterogeneity complicates and influences standard of 
care treatments and emphasizes the need for a better 
understanding of patient-specific tumor biology and 
subsequent personalized treatment planning. In line 
with this, our data showed that upon treatment with a 
non-curative dose of [177Lu]Lu-DOTA-TATE different 
areas within the tumors suffered extensive DNA 
damage induction, while other areas remained largely 
unaffected. We observed a similar pattern for the 
apoptotic response, which is extensively activated in 
certain tumor areas, but not in others. In our analyses, 
recurrent NCI-H69 tumors express the target receptor 
SST2 in a much lesser extent than treatment-naïve 
tumors, which is in sharp contrast to CA20948 where 
no decline in SST2 expression levels was observed 
after treatment. This suggests that selective pressure 
can play an important role when the target is 
heterogeneously expressed and not when it is 
homogeneously expressed, which might impact 
retreatment strategies. From PFS data in patients the 
response to retreatment regimes seems mitigated 
compared to the first cycles of PRRT [32, 33]. If 
decreased SST2 expression on a cellular level in 
recurrent lesions plays a role in these mitigated 
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retreatment responses remains to be elucidated. Since 
it has been described that occasional SST negative 
lesions also exert a higher grade of dedifferentiation 
[34] and that SST2 heterogeneity between lesions can 
impact the overall survival of patients [35], follow-up 
research could focus on the (de)differentiation status 
of NET cells after PRRT and the impact of this on 
disease progression. 
As our data showed that the distribution of 
cycling cells is homogenous throughout the tumors, 
the heterogeneous therapy response is likely not 
attributed to proliferation. Additionally, blood vessels 
were well distributed throughout the tumors and no 
association between the proximity to vessels and 
DNA damage could be found, thus it is unlikely that 
bioavailability played a major role in the therapeutic 
response observed in our study. Although it must be 
stated that these factors can play major roles in 
determining therapeutic efficacy and should not be 
disregarded without care [36, 37]. Moreover, we have 
not analyzed the functionality of the vessels or 
investigated the perfusion efficiency in these tumors, 
a factor which has also proven to be of importance to 
delivery of radioligands [38]. 
It is described that after the initial 4 cycles of 
PRRT the majority of patients will present with stable 
disease, but will eventually show disease progression 
[5, 39]. Patients that present with progressive disease 
after at least a year and that have responded well to 
the initial PRRT cycles are eligible for additional 
cycles of PRRT as it has been shown that retreatment 
is beneficial in terms of PFS and is often well tolerated 
[32, 40]. A prerequisite for (re)treatment is the 
presence of positive lesions by [68Ga]Ga-DOTA-TATE 
on a positron-emission-tomography (PET) scan, 
indicating SST2 positive tumors [40, 41]. However, 
information about the SST2 expression of single tumor 
cells within these lesions and their uptake of the 
radioligand before and after treatment is often 
unknown. Clinical response to somatostatin 
analogues is correlated with SST2 expression levels. 
Patients with higher levels of SST2 show a 
significantly higher PFS and longer overall survival 
after somatostatin analogue treatment compared to 
patients with lower SST2 expression levels [42]. Also, 
it was already shown that [68Ga]Ga-DOTA-TATE 
uptake and SST2 expression levels correlate in a 
preclinical SST2 positive xenograft model [43]. This 
was confirmed in a study focused on prostate specific 
membrane antigen (PSMA), where the investigators 
showed a correlation between PSMA expression, the 
fraction of PSMAhigh cells and therapeutic efficacy 
with a lutetium-177-labeled PSMA-targeting 
compound [44]. These findings are concomitant with 
our observation that CA20948 tumors showed higher 
[177Lu]Lu-DOTA-TATE uptake than NCI-H69 tumors, 
which subsequently led to a significant longer median 
survival after treatment. 
Although PRRT target levels and the fraction of 
positive tumor cells influence the uptake of 
radioactivity, this cannot always predict therapeutic 
efficacy. It has been shown previously that cellular 
characteristics such as p53 status can strongly 
influence the sensitivity to radiation in cancer cells 
[45]. Intrinsic differences in radiosensitivity were also 
demonstrated by analyzing the amount of DSBs after 
irradiation in a panel of cell lines, which showed that 
equivalent doses induced varying amounts of DNA 
damage in different cell lines [46]. This suggests that 
not only the absorbed dose, but also the intrinsic 
radiosensitivity can influence the therapeutic efficacy 
of PRRT. Moreover, there is little knowledge as to 
which radionuclide induces what type of DNA lesions 
exactly. In the case of lutetium-177 the vast majority of 
research has been focused on analyzing DSBs by 
measuring of either 53BP1 or γH2AX foci formation 
[10, 47, 48]. How various other types of DNA damage 
or the capacity of the target cell to repair these can 
contribute to sensitivity remains elusive. 
Interestingly, our data shows that 53BP1 and γH2AX 
foci do not exclusively overlap, which has been 
reported before [49]. What this means exactly for the 
underlying DNA damage landscape in these cells will 
warrant further investigation. 
Many different angles for improvement of 
therapeutic efficacy are currently being investigated 
as NETs become more prevalent and standard of care 
treatment is still not curative [6, 39, 50]. As we have 
shown that SST2 expression levels can influence 
cellular therapy effects, it is an interesting concept to 
stimulate SST2 expression to improve therapeutic 
outcome. Research has shown that certain epigenetic 
modulators can increase the SST2 expression of human 
pancreatic NET cells [51]. Whether this upregulation 
is limited to tumor cells and not healthy tissues 
remains to be investigated. Moreover, due to 
epigenetic heterogeneity within and between NET 
cells it is still unclear if a tailored epigenetic approach 
is necessary or possible [52]. Furthermore, the options 
of using different radionuclides, optimizing treatment 
planning, modulating target expression or applying 
other combination therapies to improve therapeutic 
outcomes for patients still warrants further 
investigation. However, before such options become 
feasible a better understanding of the radiobiological 
effects of PRRT is warranted. We believe that our data 
can contribute to such understanding in various ways. 
One option would be to use the DNA damage 
response kinetics data as a touchstone to resolve the 
ideal time-frame for potential combination therapies, 
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or to determine what time p.i. would be suitable as a 
read-out for PRRT induced DNA damage. A different 
option would be to use the SST2 heterogeneity in 
tumors as a strategy for adapted cellular 
dose-mapping to gain insight in differentially 
absorbed doses within tumors.  
In conclusion, our data deepens the current 
knowledge on the radiobiological effects of PRRT 
which can be used to investigate new avenues to 
improve therapeutic outcome. We describe pheno-
typic differences between recurrent malignancies of 
different tumor models and provide evidence for 
selective pressure in tumors that heterogeneously 
express the target receptor. 
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